INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH AND INNOVATIVE STUDIES
ISSN: 2820-7157
www.ijsrisjournal.com

December 2022 **Volume 1** **Number 3** **Pages 123-126**

Autophagy as a Common Mechanism in Chemotherapy: Mini Review

Mahdi Ali Al Ali[1], Ali Jawad Ali Alyousef[2], Mohammed Ahmad Mohammed Alhajji[2], Murtadha Abdullah Ali Alquwaythi[2], Fatema Habib Alhodibe[2], Amal Ali Yousef Al-Batyan[3], Zahra Hassan Hejji Alghanim[4], Khyraat Ahmed Majrshi[5], Sukinah Ali Yousef Alhamad[6], Merfat Saleh Alkhudair[7], Azhar Yaseen Mohammed Alhaiij[8], Nahed Mohmmad Alnazer[9], Abduljalel Ahmed Alkhames [10], Abdullah Ibrahim Alatafi[7], Mona Ali Al Shaikhsaleh[7], Norah Ali Aljannaa[7], Fawaz Yousef Albattat[11]

1.King Faisal Hospital, Saudi Arabia.

2.Al Omran General Hospital, Saudi Arabia.

3. Althlythia Health Center, Saudi Arabia.

4. PHC Alaziziah, Saudi Arabia.

5. Al-Mudayri Building, Saudi Arabia.

6. Nurse Specialist , Pediatric Department, Prince Saud Bin Jalawi Hospital, Saudi Arabia.

7. Nurse, King Fahed Hospital Hufof, Saudi Arabia.

8. Infection Control Administration, Saudi Arabia.

9. Aloyon PHC , Saudi Arabia.

10. Epidemiology Technician, North Almubbaraz PHC , Saudi Arabia.

11. Hospital Administration, Al - Mutairifi Health Center, Saudi Arabia.

ABSTRACT

Chemotherapy resistance is a significant challenge in cancer treatment, contributing to treatment failure and disease recurrence. Autophagy, a cellular process involved in the degradation and recycling of cellular components, has emerged as a common mechanism associated with chemotherapy resistance. This review explores the role of autophagy in chemotherapy resistance, focusing on its molecular mechanisms, regulation, and therapeutic implications. Understanding the interplay between autophagy and chemotherapy resistance may provide new insights into overcoming treatment resistance and improving cancer patient outcomes.

Introduction

Chemotherapy resistance remains a major obstacle in the successful treatment of cancer, leading to treatment failure, disease progression, and poor patient outcomes. Autophagy, a highly conserved cellular process, has been implicated in chemotherapy resistance in various cancer types.

Autophagy is essential for not only cell survival but also organism survival in response to microenvironmental stresses. When cancer cells are subjected to stressful conditions, autophagy is rapidly upregulated to maintain metabolic homeostasis and ensure that cell growth is appropriate to its changing environmental conditions through reduced growth and increased catabolic lysis of excessive or unnecessary proteins and organelles. However, persistent or excessive autophagy is also shown to promote cell death following treatment with specific chemotherapeutic agents, either by enhancing the induction of apoptosis or mediating ‘autophagic cell death'.

Although the molecular mechanisms whereby autophagy mediates its effects on both normal and cancer cells are far from complete, various signaling pathways have been implicated in the upregulation or downregulation of autophagy(1)(2). The phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) and AMP-activated protein kinase (AMPK) signaling pathways have emerged as the central conduit in the regulation of autophagy. mTOR can be activated by growth factors signal through the class I PI3K/Akt pathway, and inhibited by AMPK and p53(3),(4)

. Once activated, mTOR exerts a negative effect on autophagy by phosphorylating a complex of autophagy proteins (ULK1/2), which inhibits the downstream autophagy cascade(5)(6). In contrast, AMPK can suppress mTORC1 signaling to stimulate autophagy through TSC1/2 phosphorylation(7),(8). Several of the known tumor-suppressor genes (*p53*, *PTEN*, *TSC1/TSC2*) and tumor-associated genes (*p21*, *AKT*) also respectively stimulate or inhibit autophagy. By promoting cell survival under stress conditions, autophagy can confer resistance to chemotherapy-induced cell death. Understanding the molecular mechanisms underlying the crosstalk between autophagy and chemotherapy resistance is essential for developing effective therapeutic strategies to overcome treatment resistance and improve patient outcomes.

Autophagy as a Common Mechanism in Chemotherapy Resistance

1. **Molecular Mechanisms**

Autophagy can promote chemotherapy resistance through multiple mechanisms, including the removal of damaged organelles, the regulation of apoptosis, and the maintenance of cancer stem cell populations(9).

2. **Regulation of Autophagy**

The regulation of autophagy involves a complex interplay of signaling pathways and molecular mechanisms, including the PI3K/AKT/mTOR pathway, AMPK signaling, and the Beclin-1 complex(10)

3. **Therapeutic Implications**

Targeting autophagy has emerged as a promising strategy to overcome chemotherapy resistance and enhance the efficacy of anticancer therapies. Combination therapies targeting both autophagy and chemotherapy may

represent a novel approach to improving treatment outcomes(11).

Challenges and Opportunities

1. **Identification of Biomarkers:**

Biomarkers associated with autophagy and chemotherapy resistance may help predict treatment response and identify patients who are likely to benefit from autophagy-targeted therapies(12).

2. **Development of Novel Therapeutics**

The development of specific inhibitors and activators of autophagy holds promise for overcoming chemotherapy resistance and improving patient outcomes(13).

3. **Clinical Translation:**

Translating preclinical findings on autophagy modulation into clinical practice represents a significant challenge but also offers opportunities for the development of personalized treatment strategies(14).

Conclusion

Autophagy plays a critical role in chemotherapy resistance, representing a common mechanism that promotes cancer cell survival and treatment evasion. Targeting autophagy holds promise as a therapeutic strategy to overcome chemotherapy resistance and improve patient outcomes in cancer treatment. Further research is needed to elucidate the complex interplay between autophagy and chemotherapy resistance and to translate these findings into effective clinical interventions.

References

1. Glick D, Barth S, Macleod KF. Autophagy: Cellular and molecular mechanisms. Vol. 221, Journal of Pathology. 2010.
2. Cecconi F, Levine B. The Role of Autophagy in Mammalian Development: Cell Makeover Rather than Cell Death. Vol. 15, Developmental Cell. 2008.
3. Din FVN, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142(7).
4. Yu L, McPhee CK, Zheng L, Mardones GA, Rong Y, Peng J, et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature. 2010;465(7300).
5. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Vol. 43, Annual Review of Genetics. 2009.
6. Yang Z, Klionsky DJ. Mammalian autophagy: Core molecular machinery and signaling regulation. Vol. 22, Current Opinion in Cell Biology. 2010.
7. Tsuchihara K, Fujii S, Esumi H. Autophagy and cancer: Dynamism of the metabolism of tumor cells and tissues. Vol. 278, Cancer Letters. 2009.
8. Hardie DG. AMPK and Raptor: Matching Cell Growth to Energy Supply. Vol. 30, Molecular Cell. 2008.
9. Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Vol. 17, Nature Reviews Cancer. 2017.
10. Finnegan RM, Elshazly AM, Schoenlein P V., Gewirtz DA. Therapeutic Potential for Targeting Autophagy in ER+ Breast Cancer. Vol. 14, Cancers. 2022.
11. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, et al. Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment. Vol. 4, Cell Death and Disease. 2013.
12. Shang D, Xie C, Hu J, Tan J, Yuan Y, Liu Z, et al. Pancreatic cancer cell–derived exosomal microRNA-27a promotes angiogenesis of human

microvascular endothelial cells in pancreatic cancer via BTG2. J Cell Mol Med. 2020;24(1).

13. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Vol. 5, Nature Reviews Cancer. 2005.

14. Sheng J, Shen L, Sun L, Zhang X, Cui R, Wang L. Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial-lysosomal crosstalk. Cell Prolif. 2019;52(3).